Spondyloarthritis & psoriatic arthritis
HLA-Cw6 allele and biologic therapy are protective factors against liver fibrosis in psoriatic arthritis patients
Main finding · Liver fibrosis (FIB-4), multivariate logistic modelResult — go to the resultOdds ratio 0.210 95% CI 0.062–0.707Authors' conclusion
In PsA, the HLA-Cw6 allele and bDMARDs behave as protective factors for liver fibrosis, while AHT is an independent risk factor.
Study context
- Population
- Psoriatic arthritis (PsA) patients with determination of the HLA-Cw6 allele
- Participants
- 209 patients
- Exposure
- HLA-Cw6 positive vs negative; bDMARD use vs no use
- Outcome
- Liver fibrosis estimated by FIB-4 score
Methodological detailsmultivariate logistic regression
- Multivariate logistic regression
Main finding
As reported in the abstract
Liver fibrosis (FIB-4), multivariate logistic model
Odds ratio
0.210
95% CI 0.062–0.707
P = 0.012
HLA-Cw6
OR 0.210 (95% CI 0.062–0.707); P = 0.012
- HLA-Cw6 allele more frequent in PsA patients with normal FIB-4 values
- P = 0.024
Observational data: associations, not effects.
Further findings
Factors by FIB-4 status (univariate)
- HLA-Cw6 more frequent with normal FIB-4
- P = 0.024
- Arterial hypertension (AHT) more frequent with altered FIB-4
- P = 0.002
- Acute myocardial infarction (AMI) more frequent with altered FIB-4
- P = 0.023
- Dyslipidaemia more frequent with altered FIB-4
- P = 0.030
Original publication
HLA-Cw6 allele and biologic therapy are protective factors against liver fibrosis in psoriatic arthritis patients. Clin Exp Rheumatol. Published 14 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →